In a letter sent to commercial payers, the ACR’s Insurance Subcommittee is advocating for continued coverage for telemedicine, including reimbursement parity, after the end of the declared public health emergency.

RheumPAC Hosts Rep. Kim Schrier, MD, for Legislative Update
RheumPAC donors attended a virtual legislative update and Q&A with former pediatrician Rep. Kim Schrier, MD (D-Wash.), to gain an insider’s view of current healthcare legislation.

Changes in ICD-10 for Sjögren’s Syndrome
A code change in the ICD-10 classification for Sjögren’s syndrome was approved by the ICD-10 Coordination and Maintenance Committee in July 2019 and becomes effective October 2020.

Nerve Growth Factor Inhibitor Study Highlights Promise as an OA Pain Treatment
A study highlights the potential of fasinumab, an anti-nerve growth factor monoclonal antibody, as a pain treatment for osteoarthritis (OA) patients. Research into the risks and benefits of this therapeutic class for OA are ongoing…

RA Patients Taking Either 15 mg or 30 mg Dose of Upadacitinib Experience Improvement
The SELECT-EARLY MTX-controlled trial examined the safety and efficacy of upadacitinib, a potent, reversible jakinib, as monotherapy in patients with moderately to highly active RA and poor prognostic features who are either naive for or have limited exposure to methotrexate.
Oxford University to Study Adalimumab as Potential COVID-19 Treatment
LONDON (Reuters)—Oxford University said on Wednesday it will study whether the prescription medicine, adalimumab (Humira), is an effective treatment for COVID-19 patients—the latest effort to repurpose existing drugs as potential coronavirus therapies. Adalimumab, which is sold by AbbVie, is a type of anti-inflammatory known as an anti-tumour necrosis factor (anti-TNF) drug. Recent studies have shown…

FDA Receives Upadacitinib Application for Ankylosing Spondylitis & Approves Tramadol Hydrochloride Oral Solution
In August, Abbvie submitted a new drug application for upadacitinib to treat ankylosing spondylitis. And in September, the FDA approved an oral solution of tramadol hydrochloride for pain.

The Environment Within: A Possible Link Identified Between Plasma Microbial Translocation & Autoantibody Development in 1st Degree Relatives of SLE Patients
Plasma microbial translocation, the composition of the microbiome and environmental factors may influence the development of autoantibodies in patients with systemic lupus erythematosus (SLE), according to a study comparing SLE patients with their first-degree relatives and unrelated, healthy controls.
Arthroscopic Partial Meniscectomy Tied to Radiographic Knee OA
(Reuters Health)—Patients with a degenerative meniscus tear who get arthroscopic partial meniscectomy have similar five-year outcomes and increased risk of radiographic knee osteoarthritis (OA) as without surgery, a small study suggests. Researchers in Finland randomly assigned 146 adults with degenerative meniscus tear confirmed by magnetic resonance imaging (MRI) to receive either arthroscopic partial meniscectomy (APM)…
State of the Art: Lupus—the Future Is Now
Sunday, Nov. 8, 2020, 10–11:00 a.m. EST: Several lupus trials this past year had positive results, bringing hope that new therapeutics may be available in the near future. This session will discuss how advances in our understanding of lupus pathogenesis have led to the development of different therapeutic strategies. Watch this page for our report…
- « Previous Page
- 1
- …
- 177
- 178
- 179
- 180
- 181
- …
- 811
- Next Page »